Fulcrum Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Fulcrum Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2018 to 2023.
  • Fulcrum Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $1.65M, a 98.6% decline year-over-year.
  • Fulcrum Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $118M, a 40.1% increase from 2022.
  • Fulcrum Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $84.3M, a 54.8% decline from 2021.
  • Fulcrum Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $187M, a 162% increase from 2020.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $118M +$33.8M +40.1% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-27
2022 $84.3M -$102M -54.8% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-27
2021 $187M +$115M +162% Jan 1, 2021 Dec 31, 2021 10-K/A 2023-06-26
2020 $71.1M +$6.79M +10.6% Jan 1, 2020 Dec 31, 2020 10-K/A 2023-06-26
2019 $64.3M -$40.7M -38.7% Jan 1, 2019 Dec 31, 2019 10-K/A 2023-06-23
2018 $105M Jan 1, 2018 Dec 31, 2018 10-K 2020-03-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.